POST Online Media Lite Edition


Piramal Pharma Solutions to acquire solid oral dosage drug product facility in Sellersville, Pa.

Christian Fernsby |
Piramal Enterprises Limited's (PEL) Pharma Solutions business has entered into an agreement with G&W Laboratories Inc. to acquire its solid oral dosage drug product manufacturing facility located in Sellersville, Pennsylvania.

Article continues below


The transaction closure is subject to customary pre-closing conditions. According to the terms of the agreement, PEL, through one of its Affiliates, would acquire at closing a 100% stake in the entity that operates the facility and owns the related real estate.

This acquisition broadens the offering of Piramal Pharma Solutions (PPS) by adding solid oral dosage form capabilities (tablets and capsules) in North America.

Until now, PPS' capabilities in solid oral dosage forms were all located in the UK and India. The Sellersville site can also produce liquids, creams, and ointments, further expanding the PPS portfolio.

The site also can support product and process development for solid oral dosage and oral liquids, including immediate release, modified release, chewable & sublingual solid oral dosage forms, solutions and suspensions in liquids. The site has received certifications from the FDA and EMA.

The Sellersville site covers 31.5 acres of land with over 221,000 square feet of manufacturing space, including 195,000 square feet of GMP area.

What to read next

Mallinckrodt to sell Intrathecal Therapy Business for $203m
Destiny Pharma launches IPO, unveils Asian partnership
Horizon Pharma completes acquisition of Vidara Therapeutics